AXL/epidermal growth factor receptor (EGFR) complexes in breast cancer - culprits for resistance to EGFR inhibitors?

Epidermal growth factor receptor (EGFR) is highly expressed in triple-negative breast cancer (TNBC), and elevated levels correlate with poor prognosis. In analogy with the paradigm of oncogene addiction, blocking EGFR in TNBC was expected to have clinical efficacy – but this has not been the case. R...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Breast cancer research : BCR Jg. 15; H. 5; S. 315
Hauptverfasser: Heideman, Marinus R, Hynes, Nancy E
Format: Journal Article
Sprache:Englisch
Veröffentlicht: London BioMed Central 01.01.2013
Schlagworte:
Biomedical and Life Sciences
Biomedicine
Breast Neoplasms - metabolism
Cancer Research
Female
Humans
Oncology
Proto-Oncogene Proteins - metabolism
Receptor Protein-Tyrosine Kinases - metabolism
Receptor, Epidermal Growth Factor - metabolism
Signal Transduction
Surgical Oncology
Viewpoint
Epidermal Growth Factor Receptor Signaling
Epidermal Growth Factor Receptor
TNBC Subtype
Epidermal Growth Factor Receptor Inhibitor
TNBC Cell
ISSN:1465-542X, 1465-5411, 1465-542X
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Epidermal growth factor receptor (EGFR) is highly expressed in triple-negative breast cancer (TNBC), and elevated levels correlate with poor prognosis. In analogy with the paradigm of oncogene addiction, blocking EGFR in TNBC was expected to have clinical efficacy – but this has not been the case. Reasons for these results have remained elusive. Recently, Meyer and colleagues showed interplay between EGFR and the epithelial-to-mesenchymal transition-associated AXL receptor in TNBC cells, which might provide some clues.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Commentary-3
content type line 23
ISSN:1465-542X
1465-5411
1465-542X
DOI:10.1186/bcr3564